EU
FOMX

Emory University’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

Emory University’s Portfolio FOMX Stock Details FOMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-203,519
Closed -$1.01M – 57
2017
Q1 		$1.01M Buy
+203,519
New +$1.96M 0.95% 41

Other funds holding FOMX

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Emory University's FOMX Position: Q2 2017 in Review

Emory University sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q2 2017, closing a stake of 203,519 shares — an estimated $1.01M sold.

Emory University first reported a position in FOMX in Q1 2017 and held it in 1 quarter. The position peaked at $1.01M in Q1 2017. 56 funds tracked by Wall St. Rank hold FOMX as of Q2 2017.

  • Emory University reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q2 2017 after selling out during the quarter.
  • Emory University sold 203,519 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q2 2017, an estimated $1.01M.
  • Emory University first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q1 2017 and held it in 1 quarter.
  • Emory University's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $1.01M in Q1 2017.
  • 56 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q2 2017.

Based on Emory University's 13F filing for Q2 2017, filed 10 Aug 2017.